Abstract: As a refractory and special subtype of vitiligo, acral vitiligo is confronted with prominent challenges such as long treatment duration and unsatisfactory efficacy when treated with traditional topical medications and phototherapy. In recent years, with an in-depth study of the pathogenesis of vitiligo, targeted therapy has emerged as a rapidly developing frontier in this field. This paper reviews the key recent advances of targeted drugs in the treatment of acral vitiligo, with a focus on core targeted agents including JAK inhibitors and PDE-4 inhibitors, aiming to provide a reference for its clinical diagnosis and treatment.

Key words: vitiligo, acral, refractory, targeted therapy, JAK inhibitors